What is Aevumed?
Aevumed is a medical device start-up, founded by ambitious and energetic medical device professionals in the greater Philadelphia area. The company aims to advance the quality of life in patients with rotator cuff tears by providing innovative solutions that improve healing between the tendon and bone. The venture sells the PHANTOM® suture anchor, and is developing the PHANTOM-L™ and PHANTOM-X™ products to further improve healing at the tendon/bone interface.
What is rotator cuff surgery?
The rotator cuff is a bundle of muscles and tendons that hold the humeral head (the ball of the shoulder) into the glenoid (the cup of the shoulder), and allow the upper arm to mobilize. Through aging and wear, these tendons can tear away from the bone, causing pain and mobility issues. Rotator cuff surgery aims at re-attaching these tendons to the bone.
What is the market?
The extremity market is the fastest growing (10% CAGR) in orthopedics. There were over 770,000 arthroscopic rotator cuff tissue repair surgeries in 2018 and the average cost per surgery is over $3,250, making a market size of over $2.5B.
What are the clinical problems & needs?
Rotator cuff re-tears are the major complication after surgery accounting 20% of overall cases and costing over $0.5B per year. This problem is caused by; (1) Unavailability of biological devices that promote healing between tendon & bone; (2) High stresses induced by current implants; (3) relatively small surface area interface between tendon & bone.
What are Aevumed’s products?
1- PHANTOM® – FDA cleared Suture Anchor. Great pull-out strength, faster, and cost-effective.
2- PHANTOM-L™ – Lateral Row anchors for large tears. Great pull-out strength and suture retention.
3- PHANTOM-X™ – Biologic device delivery system for improved tendon and bone attachment. Efficient biologic delivery over & under tendon (Addresses clinical needs mentioned above).
Aevumed is a medical device start-up, founded by ambitious and energetic medical device professionals in the greater Philadelphia area. The company aims to advance the quality of life in patients with rotator cuff tears by providing innovative solutions that improve healing between the tendon and bone. The venture sells the PHANTOM® suture anchor, and is developing the PHANTOM-L™ and PHANTOM-X™ products to further improve healing at the tendon/bone interface.
What is rotator cuff surgery?
The rotator cuff is a bundle of muscles and tendons that hold the humeral head (the ball of the shoulder) into the glenoid (the cup of the shoulder), and allow the upper arm to mobilize. Through aging and wear, these tendons can tear away from the bone, causing pain and mobility issues. Rotator cuff surgery aims at re-attaching these tendons to the bone.
What is the market?
The extremity market is the fastest growing (10% CAGR) in orthopedics. There were over 770,000 arthroscopic rotator cuff tissue repair surgeries in 2018 and the average cost per surgery is over $3,250, making a market size of over $2.5B.
What are the clinical problems & needs?
Rotator cuff re-tears are the major complication after surgery accounting 20% of overall cases and costing over $0.5B per year. This problem is caused by; (1) Unavailability of biological devices that promote healing between tendon & bone; (2) High stresses induced by current implants; (3) relatively small surface area interface between tendon & bone.
What are Aevumed’s products?
1- PHANTOM® – FDA cleared Suture Anchor. Great pull-out strength, faster, and cost-effective.
2- PHANTOM-L™ – Lateral Row anchors for large tears. Great pull-out strength and suture retention.
3- PHANTOM-X™ – Biologic device delivery system for improved tendon and bone attachment. Efficient biologic delivery over & under tendon (Addresses clinical needs mentioned above).
Location: United States, Pennsylvania, Malvern
Employees: 1-10
Investors 2
Date | Name | Website |
- | Chemical A... | chemicalan... |
- | Ben Frankl... | sep.benfra... |
Mentions in press and media 1
Date | Title | Description |
06.08.2020 | Ben Franklin Approved $975k in 6 Early Stage Companies |